{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:04:52Z","timestamp":1791291892127,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Comparative effectiveness research has recently attracted considerable attention. The <jats:italic>C<\/jats:italic> omparative <jats:italic>E<\/jats:italic> ffectiveness <jats:italic>R<\/jats:italic> egistry to study <jats:italic>T<\/jats:italic> herapies for <jats:italic>A<\/jats:italic> rthritis and <jats:italic>I<\/jats:italic> nflammatory Co<jats:italic>n<\/jats:italic> ditions (CERTAIN) is an ongoing prospective cohort study of adult patients with Rheumatoid Arthritis (RA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Design<\/jats:title>\n            <jats:p>CERTAIN uses the existing Consortium of Rheumatology Researchers of North America (CORRONA) network of participating private and academic sites in order to recruit patients fulfilling the 1987 ACR criteria that have at least moderate disease activity. Patients starting or switching biologic agents either anti-TNF therapy or a non anti-TNF biologic are eligible for enrollment, depending on the treatment selected by their physician. Enrollment is expected to be completed by March of 2014, and 2711 patients will participate in the study. As of October 7th 2013, 2234 patients have been enrolled. Patient visits and laboratory blood work are mandated every three months for one year. Safety data is collected through one year and beyond. The primary comparative effectiveness endpoint is attainment of low RA disease activity at one year among patients who have been exposed to at least one prior TNF-\u03b1 inhibitor agent prior to enrollment. Multiple secondary effectiveness and safety endpoints will be addressed by investigating the entire population enrolled (na\u00efve and biologic experienced).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The unique design features of CERTAIN will inform comparative effectiveness and safety questions for choosing biologic agents for the management of RA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2474-15-113","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T11:03:15Z","timestamp":1396350195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients"],"prefix":"10.1186","volume":"15","author":[{"given":"Dimitrios A","family":"Pappas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"key":"2061_CR1","unstructured":"Department of Health and Human Services: comparative effectiveness funding. [http:\/\/www.effectivehealthcare.ahrq.gov\/index.cfm\/comparative-effectiveness-research-grant-and-arra-awards\/]"},{"key":"2061_CR2","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1056\/NEJMp0912651","volume":"362","author":"AI Mushlin","year":"2010","unstructured":"Mushlin AI, Ghomrawi H: Health care reform and the need for comparative-effectiveness research. N Engl J Med. 2010, 362: e6-","journal-title":"N Engl J Med"},{"key":"2061_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602.","journal-title":"N Engl J Med"},{"key":"2061_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, investigators Ts: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004, 363: 675-681.","journal-title":"Lancet"},{"key":"2061_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006, 54: 26-37.","journal-title":"Arthritis Rheum"},{"key":"2061_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1136\/ard.2007.072447","volume":"66","author":"W Kievit","year":"2007","unstructured":"Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL: The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007, 66: 1473-1478.","journal-title":"Ann Rheum Dis"},{"key":"2061_CR7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.amjmed.2008.02.018","volume":"121","author":"JD Greenberg","year":"2008","unstructured":"Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington T, Kafka SP, Reed G, Kremer JM, Consortium of Rheumatology Researchers of North America I: Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med. 2008, 121: 532-538.","journal-title":"Am J Med"},{"key":"2061_CR8","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1002\/art.22193","volume":"54","author":"A Zink","year":"2006","unstructured":"Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006, 54: 3399-3407.","journal-title":"Arthritis Rheum"},{"key":"2061_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/art.10817","volume":"48","author":"T Sokka","year":"2003","unstructured":"Sokka T, Pincus T: Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 313-318.","journal-title":"Arthritis Rheum"},{"key":"2061_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.23374","volume":"58","author":"AJ Wailoo","year":"2008","unstructured":"Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F: Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008, 58: 939-946.","journal-title":"Arthritis Rheum"},{"key":"2061_CR11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1377\/hlthaff.25.5.1340","volume":"25","author":"CD Monroe","year":"2006","unstructured":"Monroe CD, Potter L, Millares M, Barrueta A, Wagner R: Kaiser Permanente's evaluation and management of biotech drugs: assessing, measuring, and affecting use. Health Aff. 2006, 25: 1340-1346.","journal-title":"Health Aff"},{"key":"2061_CR12","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"A Officers","year":"2002","unstructured":"Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 2981-2997.","journal-title":"JAMA"},{"key":"2061_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.autrev.2005.07.006","volume":"5","author":"JM Kremer","year":"2006","unstructured":"Kremer JM: The CORRONA database. Autoimmun Rev. 2006, 5: 46-54.","journal-title":"Autoimmun Rev"},{"key":"2061_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/art.22095","volume":"55","author":"JD Greenberg","year":"2006","unstructured":"Greenberg JD, Bingham CO, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer J: Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum. 2006, 55: 543-550.","journal-title":"Arthritis Rheum"},{"key":"2061_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/art.20905","volume":"53","author":"JD Greenberg","year":"2005","unstructured":"Greenberg JD, Bingham CO, Abramson SB, Reed G, Sebaldt RJ, Kremer J: Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum. 2005, 53: 12-17.","journal-title":"Arthritis Rheum"},{"key":"2061_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/ard.2008.089276","volume":"69","author":"JD Greenberg","year":"2010","unstructured":"Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC, Investigators C: Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010, 69: 380-386.","journal-title":"Ann Rheum Dis"},{"key":"2061_CR17","first-page":"395","volume":"27","author":"JD Greenberg","year":"2009","unstructured":"Greenberg JD, Fisher MC, Kremer J, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A, Abramson SB, Investigators C: The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol. 2009, 27: 395-401.","journal-title":"Clin Exp Rheumatol"},{"key":"2061_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/rheumatology\/kep054","volume":"48","author":"JD Greenberg","year":"2009","unstructured":"Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V: Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology. 2009, 48: 686-690.","journal-title":"Rheumatology"},{"key":"2061_CR19","first-page":"560","volume":"27","author":"DE Furst","year":"2009","unstructured":"Furst DE, Chang H, Greenberg JD, Ranganath VK, Reed G, Ozturk ZE, Kremer JM: Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clin Exp Rheumatol. 2009, 27: 560-566.","journal-title":"Clin Exp Rheumatol"},{"key":"2061_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/acr.20020","volume":"62","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH: Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res . 2010, 62: 101-107.","journal-title":"Arthritis Care Res"},{"key":"2061_CR21","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/rheumatology\/kep205","volume":"48","author":"JR Curtis","year":"2009","unstructured":"Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH: Validity of physician-reported hospitalized infections in a US arthritis registry. Rheumatology. 2009, 48: 1269-1272.","journal-title":"Rheumatology"},{"key":"2061_CR22","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005, 23: S100-108.","journal-title":"Clin Exp Rheumatol"},{"key":"2061_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMp0904133","volume":"361","author":"JK Iglehart","year":"2009","unstructured":"Iglehart JK: Prioritizing comparative-effectiveness research\u2013IOM recommendations. New Engl J Med. 2009, 361: 325-328.","journal-title":"New Engl J Med"},{"key":"2061_CR24","first-page":"S447","volume-title":"Book Generalizability of a U.S. Rheumatoid Arthritis Registry: A Comparison Of Participants vs. Non-Participants' Characteristics (Editor ed.^eds.), vol. 65. pp. S447","author":"JR Curtis","year":"2013","unstructured":"Curtis JR, Chen L, Yun H, Harrold LR, Greenberg J, Kremer J: Generalizability of a U.S. Rheumatoid Arthritis Registry: a Comparison Of Participants vs. Non-Participants' Characteristics. Book Generalizability of a U.S. Rheumatoid Arthritis Registry: A Comparison Of Participants vs. Non-Participants' Characteristics (Editor ed.^eds.), vol. 65. pp. S447. 2013, S447-"},{"key":"2061_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMp0901355","volume":"360","author":"AM Garber","year":"2009","unstructured":"Garber AM, Tunis SR: Does comparative-effectiveness research threaten personalized medicine?. New Engl J Med. 2009, 360: 1925-1927.","journal-title":"New Engl J Med"},{"key":"2061_CR26","first-page":"707","volume":"11","author":"MJ Khoury","year":"2009","unstructured":"Khoury MJ, Rich EC, Randhawa G, Teutsch SM, Niederhuber J: Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine. Gen Med. 2009, 11: 707-711.","journal-title":"Gen Med"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-15-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-15-113\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-15-113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-15-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:21:57Z","timestamp":1630552917000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-15-113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2061"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-15-113","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]},"assertion":[{"value":"28 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"113"}}